Raleigh, North Carolina, and Tel Aviv, Israel, September 1, 2026
RedHill Biopharma Ltd. has announced a major expansion of its gastrointestinal (GI) commercial portfolio through the acquisition of exclusive commercialization rights to Rebyota® and Clenpiq® from Ferring Pharmaceuticals. The transaction gives RedHill exclusive global commercialization rights to Rebyota and exclusive U.S. commercialization rights to Clenpiq, strengthening its position in the gastrointestinal therapeutics market. The agreement follows RedHill’s previously announced divestiture of Talicia and represents a significant strategic repositioning toward a larger, revenue-generating GI business. Under the agreement, RedHill will pay Ferring $12 million upfront, along with potential future milestone payments and tiered royalties on net sales. The upfront payment is funded by proceeds from the previously announced $18 million Talicia divestment.
Rebyota Expands RedHill’s Microbiota-Based Portfolio
Rebyota® (fecal microbiota, live – jslm) is a proprietary, single-dose microbiota-based therapy administered rectally by a healthcare professional. It is FDA-approved for the prevention of recurrent Clostridioides difficile infection (rCDI) in adults aged 18 years and older following antibiotic treatment for recurrent infection. The therapy received FDA approval in 2022 and Health Canada approval in 2025. According to RedHill, Rebyota generated approximately $16.9 million in U.S. net sales in 2025 and had an established customer base of approximately 600 active accounts. The company also highlighted Rebyota’s previous Breakthrough Therapy and Orphan Drug designations, as well as patent and exclusivity protections that could extend to 2036. Ferring will retain its Rebyota manufacturing facilities and continue supplying the product to RedHill during the agreement term. The acquisition brings a commercially established therapy into RedHill’s portfolio for a significant infectious-disease challenge. C. difficile infection can recur after initial treatment, creating a need for strategies focused on recurrence prevention. RedHill states that Rebyota’s one-time administration has demonstrated more than a 70% success rate in preventing recurrent C. difficile infection and that broadening payer coverage has supported access in the United States. The company also sees opportunities to expand the product into additional territories following its existing approvals.
Clenpiq Adds Established Colonoscopy Preparation Product
The transaction also gives RedHill exclusive U.S. commercialization rights to Clenpiq®, a ready-to-drink, low-volume bowel preparation used to cleanse the colon before colonoscopy. Clenpiq contains sodium picosulfate, magnesium oxide and anhydrous citric acid, which together provide stimulant and osmotic laxative activity. The product is indicated for colon cleansing before colonoscopy in adults and pediatric patients aged nine years and older. RedHill reported that Clenpiq generated approximately $20.6 million in U.S. net sales during 2025, despite minimal promotion. RedHill expects Clenpiq to benefit from the continuing demand for colonoscopy procedures in the United States. The company cited more than 15 million colonoscopies performed annually and pointed to factors including an aging population, follow-up procedures after positive noninvasive screening tests and expanded screening recommendations. Clenpiq’s ready-to-drink, low-volume format is positioned as a commercially differentiated bowel-preparation option. The product also has commercial and government payer coverage, according to company-provided data. The acquisition of Rebyota and Clenpiq marks an important step in RedHill’s GI-focused commercial strategy, combining two FDA-approved products with established revenue streams. Together, the products generated approximately $37.5 million in 2025 U.S. net sales, according to RedHill. The company expects the assets to provide additional cash contribution and create a platform for further expansion through complementary product acquisitions. While the transaction strengthens RedHill’s commercial portfolio, the company noted that future performance remains subject to market acceptance, commercialization execution, regulatory considerations and other risks.
Advertisement
Source: RedHill Biopharma press release
